GB-223

N/A

Report date: 2024/05/09 13:58:00

Base Information

Drug NameGB-223
Drug Alias NameGB223注射液GB-223GB223
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsBone metastasesSolid tumoursOsteoporosis, Postmenopausal +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGenor Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGenor Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsBone metastasesSolid tumoursOsteoporosis, Postmenopausal +[4] 
Inactive IndicationsBone Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A